Bank of New York Mellon Corp Invests $2.08 Million in Janux Therapeutics, Inc. $JANX

Key Points

• Bank of New York Mellon acquired 135,072 Janux Therapeutics shares worth approximately $2.08 million, giving it a 0.22% stake. Institutional investors collectively own 75.39% of JANX.
• Janux reported a quarterly loss of $0.35 per share, missing estimates by $0.10, while revenue of $10.27 million fell short of the $19.07 million consensus forecast.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $36.46, although ratings range from “Strong Buy” to “Sell.”

Bank of New York Mellon Corp acquired a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 135,072 shares of the company's stock, valued at approximately $2,075,000. Bank of New York Mellon Corp owned approximately 0.22% of Janux Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of JANX. Nano Cap New Millennium Growth Fund L P bought a new stake in Janux Therapeutics during the 4th quarter valued at $34,000. Versant Capital Management Inc boosted its position in Janux Therapeutics by 42.8% during the second quarter. Versant Capital Management Inc now owns 2,615 shares of the company's stock valued at $40,000 after purchasing an additional 784 shares in the last quarter. Osaic Holdings Inc. boosted its position in Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company's stock valued at $80,000 after purchasing an additional 3,037 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Janux Therapeutics in the fourth quarter valued at about $51,000. Finally, Tower Research Capital LLC TRC grew its stake in Janux Therapeutics by 175.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company's stock valued at $91,000 after purchasing an additional 2,502 shares during the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Performance

Shares of NASDAQ:JANX opened at $20.24 on Tuesday. Janux Therapeutics, Inc. has a 12-month low of $12.12 and a 12-month high of $35.34. The business has a 50 day moving average of $16.68 and a two-hundred day moving average of $15.09. The company has a market capitalization of $1.24 billion, a PE ratio of -12.34 and a beta of 2.53.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.10). The firm had revenue of $10.27 million for the quarter, compared to analysts' expectations of $19.07 million. Equities research analysts predict that Janux Therapeutics, Inc. will post -1.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

JANX has been the subject of several analyst reports. TD Cowen raised shares of Janux Therapeutics to a "strong-buy" rating in a research report on Monday, August 24th. Wolfe Research raised shares of Janux Therapeutics from a "peer perform" rating to an "outperform" rating and set a $23.00 price objective on the stock in a research report on Monday, August 24th. Stifel Nicolaus set a $35.00 target price on shares of Janux Therapeutics in a research report on Friday, August 7th. Guggenheim lowered their target price on shares of Janux Therapeutics from $58.00 to $55.00 and set a "buy" rating for the company in a research note on Friday, August 7th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Janux Therapeutics in a report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $36.46.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.